The European Commission (EC) has granted conditional approval to SpringWorks Therapeutics’ Ezmekly (mirdametinib) to treat ...

Six weeks is a long time to sit in the unknown, but that’s how long I waited to find out if the 11mm tumour growing in my ...

Mirdametinib is marketed under the brand name EZMEKLY® in the European Union and is conditionally approved by the European ...

Plexiform neurofibromas can transform into malignant peripheral nerve sheath tumors, an aggressive and potentially fatal disease. 5 Surgical removal can be challenging due to the infiltrative ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer is no longer just a disease of ...

Unlike the brain and spinal cord, peripheral nerve cells, whose long extensions reach the skin and internal organs, are capable of regenerating after injury. This is why injuries to the central ...

Hispanic folks were 32% more likely than white people to have this nerve disorder even after accounting for known health, lifestyle and social risk factors, researchers reported July 16 in the ...

Experts see tolebrutinib as part of a broader shift toward treatments that target the neurodegeneration in MS, not just its ...

These tumors grow in an infiltrative pattern along the peripheral nerve sheath and can cause severe disfigurement, pain and functional impairment. 3,4 Plexiform neurofibromas can transform into ...